Published: 1 June 2017
Author(s): Michael Lichtenauer, Peter Jirak, Bernhard Wernly, Vera Paar, Ilonka Rohm, Christian Jung, Christiana Schernthaner, Johannes Kraus, Lukas J. Motloch, Atilla Yilmaz, Uta C. Hoppe, P. Christian Schulze, Daniel Kretzschmar, Rudin Pistulli
Issue: June 2017
Section: Original Article

Heart failure (HF) with reduced ejection fraction remains a major therapeutic challenge. The aim of this study was to investigate the role of novel cardiovascular biomarkers, i.e. soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) in patients with ischaemic (ICM) or dilative cardiomyopathy (DCM).

Newsletters

Stay informed on our latest news!